- Email: [email protected]
5354555 Vaccine to control the viral infection of fish
New Patents glycopmtein selected from the group consisting of gI, gp50, and gp63, host cells transformed by said recombinant DNA molecule sequences, the gl, gp50 and gp63 polypeptides. The present invention also provides subunit vaccines for PRV, methods for protecting animals against PRV infection and methods for distinguishing between infected and vaccinated animals.
5352596 PSEUDORABIES VIRUS DELETION MUTANTS INVOLVING THE EPO AND LLT GENES Cheung Andrew; Wesley Ronald The United States of America as represented by the Secretary of Agriculture An attenuated pseudorabies virus (PRV) having a reduced ability to reactivate from latency is produced by introducing (1) a genomic modification in the early protein 0 (EP0) gene whereby said virus is characterized by the inability to express the early protein 0; or (2) a genomic modification in the large latency transcript (LLT) gene whereby said virus is characterized by disruption of the synthesis of said large latency transcript; or (3) the genomic modifications described in both (1) and (2). The attenuated virus is useful in a vaccine for psuedorabies-susceptible animals, particularly swine. Swine vaccinated with a deletion mutant in the EP0/LLT overlap region displayed reduced virus shedding and fewer clinical signs than animals inoculated with a wild type virus. The deletion mutant-vaccinated swine also harbored less PRV DNA in the nervous tissue and showed reduced ability to reactivate the virus.
5352783 MICROBIAL TRANSFORMATION PRODUCT HAVING IMMUNOSUPPRESSIVE ACTIVITY Shafiee Ali; Arison Byron; Chen Shieh-Shung T; Miller Randall; Stearns Ralph Merck & Co Inc
VII
Microbial transformation of a maerolide immunosuppressant by the microorganism Streptomyces sp., (Merck Culture Collection MA 6960) ATCC No. 55387 yields a compound of the structural formula (I): (*See Patent for Chemical Structure*) I (*See Patent for Tabular Presentation*) This compound is an immunosuppressant useful in a mammalian host for the treatment of autoimmune diseases, infectious diseases, the prevention of rejection of foreign organ transplants and/or related afflictions, diseases and illnesses.
5354555 VACCINE TO CONTROL THE VIRAL INFECTION OF FISH Leong Jo-Ann C, Albany, OR, UNITE[) STATES State of Oregon Acting By and Through The State Board of Higher Education on Behalf of Oregon State University Subunit vaccines and their use for immunizing fish against infection by viruses are disclosed. In particular, plasmid pG8 is constructed by joining, with the plasmid pUC8, DNA which encodes the glycopmtein of infectious hematopoietic necrosis virus (IHNV). E. coli cells are transformed by pG8, whereby pure viral antigen is produced to provide a vaccine for the control of IHNV in fish.
5354659 METHOD FOR DETECTING PATHOLOGICAL PREGNANCY Rothlein Robert; Marlin Steven D Ingelheim Pharmaceuticals Inc
Boehringer
A method for the detection of the presence of inflammation in a patient by measuring the amount of circulating intercellular adhesion molecule (cICAM-1) in a sample of one or more bodily fluids of the patient and then comparing the amount of clCAM-1 in the sample to standards normal for the bodily fluid or fluids assayed. The amount of cICAM-I can be measured using anti-ICAM-I antibodies. Higher
5352596 PSEUDORABIES VIRUS DELETION MUTANTS INVOLVING THE EPO AND LLT GENES Cheung Andrew; Wesley Ronald The United States of America as represented by the Secretary of Agriculture An attenuated pseudorabies virus (PRV) having a reduced ability to reactivate from latency is produced by introducing (1) a genomic modification in the early protein 0 (EP0) gene whereby said virus is characterized by the inability to express the early protein 0; or (2) a genomic modification in the large latency transcript (LLT) gene whereby said virus is characterized by disruption of the synthesis of said large latency transcript; or (3) the genomic modifications described in both (1) and (2). The attenuated virus is useful in a vaccine for psuedorabies-susceptible animals, particularly swine. Swine vaccinated with a deletion mutant in the EP0/LLT overlap region displayed reduced virus shedding and fewer clinical signs than animals inoculated with a wild type virus. The deletion mutant-vaccinated swine also harbored less PRV DNA in the nervous tissue and showed reduced ability to reactivate the virus.
5352783 MICROBIAL TRANSFORMATION PRODUCT HAVING IMMUNOSUPPRESSIVE ACTIVITY Shafiee Ali; Arison Byron; Chen Shieh-Shung T; Miller Randall; Stearns Ralph Merck & Co Inc
VII
Microbial transformation of a maerolide immunosuppressant by the microorganism Streptomyces sp., (Merck Culture Collection MA 6960) ATCC No. 55387 yields a compound of the structural formula (I): (*See Patent for Chemical Structure*) I (*See Patent for Tabular Presentation*) This compound is an immunosuppressant useful in a mammalian host for the treatment of autoimmune diseases, infectious diseases, the prevention of rejection of foreign organ transplants and/or related afflictions, diseases and illnesses.
5354555 VACCINE TO CONTROL THE VIRAL INFECTION OF FISH Leong Jo-Ann C, Albany, OR, UNITE[) STATES State of Oregon Acting By and Through The State Board of Higher Education on Behalf of Oregon State University Subunit vaccines and their use for immunizing fish against infection by viruses are disclosed. In particular, plasmid pG8 is constructed by joining, with the plasmid pUC8, DNA which encodes the glycopmtein of infectious hematopoietic necrosis virus (IHNV). E. coli cells are transformed by pG8, whereby pure viral antigen is produced to provide a vaccine for the control of IHNV in fish.
5354659 METHOD FOR DETECTING PATHOLOGICAL PREGNANCY Rothlein Robert; Marlin Steven D Ingelheim Pharmaceuticals Inc
Boehringer
A method for the detection of the presence of inflammation in a patient by measuring the amount of circulating intercellular adhesion molecule (cICAM-1) in a sample of one or more bodily fluids of the patient and then comparing the amount of clCAM-1 in the sample to standards normal for the bodily fluid or fluids assayed. The amount of cICAM-I can be measured using anti-ICAM-I antibodies. Higher